Gallium nitrate

Phase 2Radiopharmaceutical

GGenta Incorporated

Gallium nitrate is one of 106 small molecule programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

105

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Cystic FibrosisActive, not recruiting

RhabdomyosarcomaActive, not recruiting

LymphomaPhase 2

Active, not recruiting

Cystic FibrosisPhase 1

Active, not recruiting

RhabdomyosarcomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Oncaspar

SServier

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Gallium nitrate

GGenta Incorporated

Phase 2

2 6

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 7

Tafasitamab

Incyte

Preclinical

7 8

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 10

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Cystic Fibrosis

NCT04294043

Clinical

Trials by Indication[1]

Cystic Fibrosis2 trials

IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)

Recruiting·CChris Goss·Phase 1·NCT04294043·40 enrolled

A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)

Completed·UUniversity of Washington·Phase 2·NCT02354859·119 enrolled

Lymphoma2 trials

Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00002578·35 enrolled

Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed·GGenta Incorporated·Phase 2·NCT00054808·40 enrolled

Rhabdomyosarcoma1 trial

Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors

Completed·MMedical College of Wisconsin·Phase 1·NCT00002543·3 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Gallium nitrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gallium nitrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gallium nitrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Genta Incorporated company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Highest Phase: Phase 2[1]
Company: GGenta Incorporated

Gallium nitrate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Cystic Fibrosis2 trials

Lymphoma2 trials

Rhabdomyosarcoma1 trial

References

Drug Info

Quick Facts

Related News